ORG Partners LLC Makes New $527,000 Investment in Laboratory Co. of America Holdings (NYSE:LH)

ORG Partners LLC acquired a new stake in Laboratory Co. of America Holdings (NYSE:LH) in the 4th quarter, Holdings Channel.com reports. The institutional investor acquired 2,298 shares of the medical research company’s stock, valued at approximately $527,000.

Other hedge funds have also modified their holdings of the company. Ashton Thomas Private Wealth LLC purchased a new position in Laboratory Co. of America during the 2nd quarter worth $118,000. Choreo LLC acquired a new position in Laboratory Co. of America in the 2nd quarter valued at about $432,000. Daiwa Securities Group Inc. raised its stake in Laboratory Co. of America by 9.2% during the 2nd quarter. Daiwa Securities Group Inc. now owns 10,355 shares of the medical research company’s stock valued at $2,108,000 after acquiring an additional 873 shares during the last quarter. American Century Companies Inc. lifted its position in Laboratory Co. of America by 1.9% during the 2nd quarter. American Century Companies Inc. now owns 749,819 shares of the medical research company’s stock worth $152,596,000 after acquiring an additional 14,277 shares during the period. Finally, Johnson Investment Counsel Inc. acquired a new position in shares of Laboratory Co. of America in the second quarter valued at approximately $247,000. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Laboratory Co. of America Trading Down 0.9 %

Shares of LH stock opened at $232.12 on Friday. Laboratory Co. of America Holdings has a twelve month low of $191.97 and a twelve month high of $247.99. The company has a market capitalization of $19.41 billion, a price-to-earnings ratio of 44.90, a PEG ratio of 1.91 and a beta of 1.06. The firm has a 50-day moving average price of $234.59 and a 200 day moving average price of $224.49. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.66.

Laboratory Co. of America (NYSE:LH) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $3.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.02. The business had revenue of $3.28 billion for the quarter, compared to the consensus estimate of $3.26 billion. Laboratory Co. of America had a net margin of 3.43% and a return on equity of 15.27%. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.38 earnings per share. Research analysts forecast that Laboratory Co. of America Holdings will post 14.52 earnings per share for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Stockholders of record on Thursday, February 27th will be given a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.24%. Laboratory Co. of America’s dividend payout ratio is currently 55.71%.

Analysts Set New Price Targets

LH has been the topic of several recent research reports. StockNews.com cut shares of Laboratory Co. of America from a “buy” rating to a “hold” rating in a research note on Friday, October 25th. Piper Sandler lifted their price objective on Laboratory Co. of America from $235.00 to $240.00 and gave the company a “neutral” rating in a report on Monday, October 28th. Barclays raised their price target on Laboratory Co. of America from $234.00 to $249.00 and gave the company an “equal weight” rating in a report on Friday, October 25th. Bank of America raised their target price on Laboratory Co. of America from $262.00 to $271.00 and gave the company a “buy” rating in a report on Friday, December 13th. Finally, Hsbc Global Res upgraded shares of Laboratory Co. of America from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 30th. Four analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Laboratory Co. of America currently has an average rating of “Moderate Buy” and a consensus price target of $260.54.

Insider Activity at Laboratory Co. of America

In other Laboratory Co. of America news, CEO Adam H. Schechter sold 6,189 shares of Laboratory Co. of America stock in a transaction on Monday, November 11th. The shares were sold at an average price of $243.47, for a total value of $1,506,835.83. Following the transaction, the chief executive officer now owns 87,441 shares in the company, valued at $21,289,260.27. This trade represents a 6.61 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Kerrii B. Anderson sold 1,000 shares of the business’s stock in a transaction on Thursday, October 24th. The shares were sold at an average price of $230.00, for a total transaction of $230,000.00. Following the sale, the director now directly owns 13,722 shares of the company’s stock, valued at $3,156,060. This represents a 6.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 25,572 shares of company stock worth $6,145,209. 0.85% of the stock is currently owned by insiders.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.